论文部分内容阅读
目的:研究分析尿毒症患者高通量血液透析前后血清可溶性转铁蛋白受体水平指标变化情况及影响因素。方法:选取该院2014年11月至2015年11月期间收治的43例尿毒症患者,所有患者均行高通量血液透析治疗,对比分析不同时间(治疗前、2个月、半年、一年)段患者血液可溶性转铁蛋白受体水平的变化情况。结果:患者接受高通量透血液透析之后两个月、半年和一年与接受透析之前相比较,患者血液可溶性转铁蛋白受体水平明显降低,数据差异显著(P<0.05)。结论:对尿毒症患者应用高通量血液透析方法能够达到预期临床治疗效果,改善患者贫血的情况,抑制病情发展,在临床中应用具有重要意义。
OBJECTIVE: To study the change of serum soluble transferrin receptor level before and after high-flux hemodialysis in uremic patients and its influencing factors. Methods: Forty-three patients with uremia admitted from November 2014 to November 2015 in our hospital were enrolled in this study. All patients underwent high-flux hemodialysis. The patients were treated at different times (before treatment, two months, six months, one year ) Section of patients with blood soluble transferrin receptor level changes. Results: Compared with those before dialysis, the level of soluble transferrin receptor in patients after two-month, six-month and one-year high-dose hemodialysis was significantly lower (P <0.05). Conclusion: The application of high-throughput hemodialysis in patients with uremia can achieve the expected clinical effect, improve the patient’s anemia, inhibit the progression of the disease, which is of great significance in the clinical application.